entertainment -WSS

entertainment

author：hotspot 2025-10-01 05:39:31 - browse：323

Insitro CEO and founder Daphne Koller Neilson Barnard/Getty Images for The New York Times

SAN FRANCISCO — It took only a single, one-hour meeting in a Starbucks to convince venture capitalist Robert Nelsen that he was going to invest in the company being built by machine-learning whiz Daphne Koller. “She’s just an amazing force of nature,” said Nelsen, who invests for ARCH Venture Partners.

Koller’s company, Insitro, in a matter of months raised over $100 million from big-name investors including ARCH, Foresite Capital, Andreessen Horowitz, and the firm that manages Jeff Bezos’ personal VC investments. (Koller refers to Bezos by his first name.) Now, it’s time for the next step. On Tuesday, the giant drug maker Gilead Sciences said it would pay Insitro $15 million — and up to $1 billion more down the line if it meets certain goals — for help in developing drugs to treat a common liver disease. It is the South San Francisco-based company’s first deal with a drug maker, and offers a test of whether artificial intelligence can remake drug development.

The very nature of the financials emphasize the exciting but risky reality: The technology has great promise, but nothing is guaranteed.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Sanofi to acquire U.S. biotech Inhibrx in $2.2 billion deal

hotspot

WSS

Mass General, Mayo Clinic look to monetize custom

Cardiologists urge adding sexual orientation, gender identity to health records

How corporate America is slashing DEI workers amid backlash to diversity programs

FDA sets aggressive timeline for overhauling inspection procedures

How corporate America is slashing DEI workers amid backlash to diversity programs

With fresh data, a dynamic duo powers Eli Lilly to new heights

focus

entertainment

Wikipedia

Affirmative action in medical school literally saved lives

FDA endorses new sterilization method for medical devices

Walensky prepares to leave CDC — and Congress — behind

Head of FDA's diagnostics center, who led through Covid, retires

Continuity nursing helped my family in our darkest PICU moments

Dana Farber says 6 studies to be retracted and 31 corrected

Bright Health sells Medicare Advantage business to Molina

What to know about a major upcoming Wegovy heart health study

How to save PrEP access — and even expand it

House panel to mark up pandemic

focus

FDA sets aggressive timeline for overhauling inspection procedures

Prior authorization reform is both possible and imperative

HPV vaccine, cervical cancer study delivers historic results

What could happen if Russia blows up the Zaporizhzhia Nuclear Power Plant?

Sanofi to acquire U.S. biotech Inhibrx in $2.2 billion deal

US intelligence assessment says Iran not currently developing nuclear weapons

focus

knowledge

hotspot

hotspot